A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

AHS Cancer Control Alberta

Status and phase: Completed; Phase 2

Conditions: Prostatic Neoplasms; Neoplasm Metastasis; Palliative Care

Treatments: Behavioral: Exercise training

Study type: Interventional

Funder types: Other

Identifiers

NCT00271687

SP-14-0049 / 22262

Details and patient eligibility

About

This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.

Enrollment: 30 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of prostate cancer
• receiving docetaxel-based chemotherapy at the CCI
• age 18 years or over
• approval of oncologist
• informed written consent

Exclusion criteria

• life expectancy less than 6 months
• Karnofsky performance score less than 70
• contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
• unable to understand, read, write and speak English
• unable or unwilling to attend supervised exercise sessions 3 times weekly
• unable or unwilling to complete outcome assessments

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)